Navigation Links
Immtech Reports Fiscal Third Quarter 2008 Results

NEW YORK, Feb. 11 /PRNewswire-FirstCall/ -- Immtech Pharmaceuticals, Inc. (the "Company") (Amex: IMM) today announced results for its fiscal third quarter ended December 31, 2007.

For the three months ended December 31, 2007, revenues were $1,835,000, as compared to $546,000 for the three months ended December 31, 2006. The increase was primarily attributable to revenues relating to a licensing agreement and research agreement. Loss from operations for the three months ended December 31, 2007 was $5,305,000, as compared to a loss from operations of $3,946,000 for the three months ended December 31, 2006. The increase was primarily due to an increase in clinical trial costs. Net loss attributable to common stockholders for the three months ended December 31, 2007 was $5,336,000, or $0.34 per share, compared to a loss of $3,966,000, or $0.28 per share, in the previous year.

At December 31, 2007, unrestricted cash and cash equivalents were $9,444,000 as compared to $12,462,000 at March 31, 2007. For the same periods, restricted funds on deposit were $4,962,000 and $3,119,000, respectively.

The Company reported today that it is studying clinical trial data collected in all prior and ongoing clinical trials of pafuramidine in order to address the clinical hold. The clinical hold was made in response to abnormal liver findings in Phase I safety study subjects, as reported in a Company press release dated December 26, 2007.

Information to access a recording of the conference call to be held on February 11, 2008 at 4.30pm will be available starting on February 12th from the Immtech Pharmaceuticals web site (

About Immtech Pharmaceuticals, Inc.

Immtech Pharmaceuticals, Inc. is focused on developing and commercializing drugs to treat infectious diseases, and is expanding its targeted markets by applying its proprietary pharmaceutical platform to treat other disorders. Immtech has advanced clinical programs that include new oral treatments for pneumocystis pneumonia (PCP), malaria, and trypanosomiasis (HAT or African sleeping sickness), and a well-defined, expanding library of compounds targeting drug-resistant Gram-positive bacteria, fungal infections, Hepatitis C and other serious diseases. Immtech holds the exclusive worldwide licenses to certain patents, patent applications and technology for products derived from a proprietary pharmaceutical platform. For additional information, please visit the Company's website at

This press release contains "forward-looking statements" regarding Immtech Pharmaceuticals, Inc.'s business, including the future prospects for PCP. Except for historical information, the matters discussed in this press release are "forward-looking statements" and are subject to risks and uncertainties. Actual results could differ materially from these forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, the following: (i) Immtech's ability to develop commercially viable products; (ii) Immtech's ability to achieve profitability; (iii) Immtech's ability to retain key personnel; (iv) the ability of Immtech's scientists and collaborators to discover new compounds; (v) the availability of additional research grants; (vi) Immtech's ability to obtain regulatory approval of its drug candidates, including PCP; (vii) the success of Immtech's clinical trials; (viii) dependence upon and contractual relationship with partners; (ix) Immtech's ability to manufacture or to contract with a third party to manufacture its drug candidates at a reasonable cost; (x) Immtech's ability to protect its intellectual property; (xi) competition and alternative technologies; (xii) Immtech's ability to obtain reimbursement from third party payers for any product it commercializes; and (xiii) potential exposure to significant product liability.

Additional risks are discussed in the Company's current filings with the Securities and Exchange Commission. Although the Company believes the expectations reflected in such forward-looking statements are based on reasonable assumptions, it can give no assurance that its expectations will be attained. The forward-looking statements are made as of the date of this press release, and we undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.

Immtech Pharmaceuticals, Inc.

Selected Financial Information (Unaudited)

(in thousands, except per share amounts)

Three Months Ended

December 31,

2007 2006

REVENUES $1,835 $546

OPERATING LOSS $(5,305) $(3,946)


COMMON STOCKHOLDERS $(5,336) $(3,966)


BASIC AND DILUTED $(0.34) $(0.28)


Basic and diluted 15,534,138 14,108,835

SOURCE Immtech Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Immtech Investor Conference Call Scheduled for February 11, 2008
2. Immtech and BioAlliance Sign Licensing Agreement for Pafuramidine
3. Immtech to Present at The Bank of Montreal Healthcare Conference
4. Phlo Affiliate Reports Progress in New York City Metropolitan Area Roll-Out
5. Cryo-Cell International, Inc. Reports Results for Fiscal 2007
6. Uroplasty Reports Record Sales for Third Fiscal Quarter and Nine Months Ended December 31, 2007
7. Bunge Reports Fourth Quarter Net Income of $245 Million
8. Digirad Corporation Reports Financial Results for 2007 Fourth Quarter and Twelve Months
9. ThermoGenesis Corp. Reports 48 Percent Growth in Second Quarter Revenues Year Over Year
10. Senesco Technologies Reports on Results of Preclinical Multiple Myeloma Studies
11. Recent Research Reports and Near-Term Corporate Events
Post Your Comments:
(Date:6/23/2016)... Calif. , June 23, 2016  Blueprint Bio, ... biological discoveries to the medical community, has closed its ... Matthew Nunez . "We have received ... with the capital we need to meet our current ... essentially provide us the runway to complete validation on ...
(Date:6/23/2016)... ... June 23, 2016 , ... ClinCapture, the only ... Center and will showcase its product’s latest features from June 26 to June ... scientific poster on Disrupting Clinical Trials in The Cloud during the conference. ...
(Date:6/23/2016)... -- Amgen (NASDAQ: AMGN ) today announced a ... sciences incubator to accelerate the development of new therapies ... QB3@953 was created to help high-potential life science and ... stage organizations - access to laboratory infrastructure. ... "Amgen Golden Ticket" awards, providing each winner with one ...
(Date:6/22/2016)... , June 22, 2016 Research and ... Global Markets" report to their offering. ... billion in 2014 from $29.3 billion in 2013. The market is ... of 13.8% from 2015 to 2020, increasing from $50.6 billion in ... projected product forecasts during the forecast period (2015 to 2020) are ...
Breaking Biology Technology:
(Date:4/28/2016)... 28, 2016 First quarter 2016:   ... compared with the first quarter of 2015 The gross ... M (loss: 18.8) and the operating margin was 40% (-13) ... Cash flow from operations was SEK 249.9 M (21.2) , ... is unchanged, SEK 7,000-8,500 M. The operating margin for ...
(Date:4/15/2016)... , April 15, 2016 ... the,  "Global Gait Biometrics Market 2016-2020,"  report to ... ) , ,The global gait biometrics ... of 13.98% during the period 2016-2020. ... angles, which can be used to compute factors ...
(Date:3/29/2016)... 29, 2016 LegacyXChange, Inc. (OTC: ... and SelectaDNA/CSI Protect are pleased to announce our successful ... a variety of writing instruments, ensuring athletes signatures against ... collectibles from athletes on LegacyXChange will be assured of ... DNA. Bill Bollander , CEO states, ...
Breaking Biology News(10 mins):